Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically…mehr
Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Dr. O'Bryan received his Ph.D. from the University of North Carolina at Chapel Hill. He then pursued postdoctoral studies at the Samuel Lunenfeld Institute in Toronto, Canada and the University of North Carolina at Chapel Hill. Dr. O'Bryan then established his independent research program at the National Institute of Environmental Health Science, NIH in Research Triangle Park before being recruited to the University of Illinois at Chicago. In 2018, he was recruited to the NCI-Designated Hollings Cancer Center at MUSC where he is Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics and Director of Graduate Studies. In addition, Dr. O'Bryan has a joint appointment as a Research Health Scientist at the Ralph H. Johnson VA Medical Center. Dr. O'Bryan's research interests have centered on understanding the regulation of cell signaling pathways involved in normal and pathophysiological conditions, particularly cancer. His current research is focus
ed on defining vulnerabilities in RAS that can be exploited for the development of new therapeutics for the treatment of RAS mutant cancers. His research is supported by grants from the National Institutes of Health, the Veterans Administration, and various private foundations.
Inhaltsangabe
1. A brief history of RAS and the RAS Initiative Frank McCormick 2. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations Rachel A. Burge and G. Aaron Hobbs 3. Drug targeting opportunities en route to Ras nanoclusters Karolina Pavic, Rohan Chippalkatti, and Daniel Abankwa 4. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan-Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, and Channing J. Der 5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone Alexander B. Coley, Antonio Ward, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Aishwarya Prakash, Feng Li, Jeremy B. Foote, Donald J. Buchsbaum, and Gary A. Piazza 6. Targeting RAS oncogenesis with SOS1 inhibitors Roman Christian Hillig and Benjamin Bader 7. Inhibition of SHP2 as an approach to block RAS-driven cancers Yu-Ting Chou and Trever G. Bivona 8. Targeting the "undruggable RAS with biologics Michael Whaby, Imran Khan, and John P. O'Bryan 9. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain Jonathan M. DeLiberty, Ryan Robb, Claire E. Gates, and Kirsten L. Bryant 10. The RASopathies: Biology, genetics and therapeutic options Jody Fromm Longo and Steven L. Carroll
1. A brief history of RAS and the RAS Initiative Frank McCormick 2. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations Rachel A. Burge and G. Aaron Hobbs 3. Drug targeting opportunities en route to Ras nanoclusters Karolina Pavic, Rohan Chippalkatti, and Daniel Abankwa 4. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan-Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, and Channing J. Der 5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone Alexander B. Coley, Antonio Ward, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Aishwarya Prakash, Feng Li, Jeremy B. Foote, Donald J. Buchsbaum, and Gary A. Piazza 6. Targeting RAS oncogenesis with SOS1 inhibitors Roman Christian Hillig and Benjamin Bader 7. Inhibition of SHP2 as an approach to block RAS-driven cancers Yu-Ting Chou and Trever G. Bivona 8. Targeting the "undruggable RAS with biologics Michael Whaby, Imran Khan, and John P. O'Bryan 9. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain Jonathan M. DeLiberty, Ryan Robb, Claire E. Gates, and Kirsten L. Bryant 10. The RASopathies: Biology, genetics and therapeutic options Jody Fromm Longo and Steven L. Carroll
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
